Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
IDH1-mutated cancers
|
| gptkbp:alsoKnownAs |
gptkb:Ivosidenib
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX65
|
| gptkbp:CASNumber |
1448347-49-6
|
| gptkbp:chemicalFormula |
C28H22N8O3
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Agios_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
AG-120
|
| gptkbp:indication |
gptkb:acute_myeloid_leukemia
cholangiocarcinoma |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
IDH1 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
QT prolongation
leukocytosis differentiation syndrome |
| gptkbp:target |
gptkb:isocitrate_dehydrogenase_1_(IDH1)
|
| gptkbp:bfsParent |
gptkb:IDH1_gene
gptkb:ivosidenib |
| gptkbp:bfsLayer |
7
|